Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens

Carpenter, Christopher; Chambers, Henry F.

doi:10.1086/383472

Cited by 331 publications

(184 citation statements)

References 18 publications

Supporting

Mentioning

174

Contrasting

Unclassified

Order By: Relevance

“…The PK of DAP are not altered in subjects with mild-to-moderate hepatic impairment, compared with healthy volunteers, whereas the PK in patients with severe hepatic impairment have not been studied; therefore, caution is advised in the patient with severe hepatic impairment. 6,7 Tigecycline (TGC) is a derivative of minocycline. The two major metabolic pathways of TGC consist of glucuronidation, and amide hydrolysis to t-butylaminoacetic acid and 9-aminominocycline.…”

Section: Letters To the Editorsmentioning

confidence: 99%

Letter: antibiotic dose adjustment in patients with advanced liver disease

Leone

Rossi

Bisi

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Section: Letters To the Editorsmentioning

confidence: 99%

Letter: antibiotic dose adjustment in patients with advanced liver disease

Leone

Rossi

Bisi

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

“…The following antibacterial agents have been approved during the last five years: quinupristin/dalfopristin, [29][30][31][32] linezolid, 33,34 daptomycin, [35][36][37] and tigecycline. 38,39 Novel lipoglycopeptide agents under study include dalbavancin, 40 telavancin, and oritavancin.…”

Section: Novel Antibacterial Agents With Enhanced Activity Against Rementioning

confidence: 99%

Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Manfredi¹,

Sabbatani²

2010

Braz J Infect Dis

View full text Add to dashboard Cite

Introduction: methicillin-and also vancomycin (glycopeptide)-resistant Gram-positive organisms have emerged as an increasingly problematic cause of hospital-acquired infections, also spreading into the community. Vancomycin (glycopeptide) resistance has emerged primarily among Enterococci, but the MIC values of vancomycin for the entire Staphylococcus species are also increasing worldwide. Material and Methods: the aim of our review is to evaluate the efficacy and tolerability of newer antibiotics with activity against methicillin-resistant and glycopeptide-resistant Gram-positive cocci, on the ground of our experience at a tertiary care metropolitan Hospital, and the most recent literature evidences in this field. Results: Quinupristin-dalfopristin, linezolid, daptomycin, and tigecycline show an excellent in vitro activity, comparable to the activity of vancomycin and teicoplanin for methicillin-resistant staphylococci, and superior to the one that vancomycin for vancomycin-resistant isolates. Dalbavancin, televancin, and oritavancin are new lipoglycopeptide agents with excellent activity against Gram-positive cocci, and have superior pharmacodynamics properties compared to vancomycin. We review the bacterial spectrum, clinical indications and practical use, pharmacologic properties, and expected adverse events and contraindications associated with each of these novel antimicrobial agents, compared with the present standard of care. Discussion: linezolid activity is substantially comparable to that of vancomycin in patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, although its penetration into the respiratory tract is exceptionally elevated. Tigecycline has activity against both Enterococus species and MRSA; it is also active against a broad spectrum of Enterobacteriaceae and anaerobes, which allows for use intraabdominal, diabetic foot and surgical infections. Daptomycin has a rapid bactericidal activity for Staphylococcus aureus and it is approved in severe complications, such as bacteremia and right-sided endocarditis. It cannot be used to treat pneumonia and respiratory diseases, due to its inactivation in the presence of pulmonary surfactant.

show abstract

“…It is unknown if this also applies to patients with intra-abdominal infections due to this organism. Quinupristin/dalfopristin and daptomycin are alternative agents with activity against MRSA [69,70], but experience in the treatment of intra-abdominal infections with these antimicrobials is quite limited as well. Tigecycline also has in vitro activity against MRSA, and has been studied in both skin and soft tissue infections and lowerrisk intra-abdominal infections.…”

Section: Antimicrobial Therapy For Higher-risk Patients With Intra-abmentioning

confidence: 99%

Clinical Challenges and Unmet Needs in the Management of Complicated Intra-abdominal Infections

Mazuski

2005

Surgical Infections

View full text Add to dashboard Cite

Methods: Based on a review of the literature, treatment guidelines, and expert opinion, the challenges of managing patients with complicated intra-abdominal infections are summarized using a patient stratification approach: "Lower risk" of treatment failure and death vs. "higher risk."Results: Risk factors for treatment failure and death can be grouped into several categories, including the patient's pre-existing medical comorbidities and physiological response to the infection, the extent of the intra-abdominal infection, and the presence of specific pathogenic microorganisms. These latter factors may be more useful than the Acute Physiology and Chronic Health Evaluation (APACHE) II score in evaluating specific management strategies for patients with complicated intra-abdominal infections. The principal goal of treatment in lower-risk patients is to avoid morbidity related to source control procedures and antimicrobial therapy. Limitation of the scope of source control procedures and utilization of short-duration, narrow-spectrum, low-toxicity antimicrobial regimens is advisable to avoid adverse drug reactions and selection of resistant organisms. For higher-risk patients, the goal is to develop improved management modalities, so that morbidity and mortality are reduced. The recommended approach for higher-risk patients is to identify the most appropriate source control procedure and antimicrobial therapy, as dictated by the patient's specific risk factors, and to utilize the optimal tools of critical care medicine to treat these critically ill, septic patients. The emergence of bacterial resistance also must be considered when selecting antimicrobial therapy for both low risk and high risk patients with intra-abdominal infections. Because aminoglycoside regimens are becoming less favored, and optimal therapeutic strategies have not been standardized, the use of new treatment options (e.g., tigecycline) may be valuable when managing patients with intra-abdominal infections. especially for resistant isolates.Conclusions: The management of lower-risk patients with intra-abdominal infections is distinct compared with patients at higher risk due to compromised physiological status, extent of intra-abdominal infection, or presence of nosocomial pathogens associated with higher-

show abstract

Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens

Cited by 331 publications

References 18 publications

Letter: antibiotic dose adjustment in patients with advanced liver disease

Letter: antibiotic dose adjustment in patients with advanced liver disease

Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Clinical Challenges and Unmet Needs in the Management of Complicated Intra-abdominal Infections

Contact Info

Product

Resources

About